WO2002067895A3 - Implant dosage form and use thereof for the delivery of a cholesterol lowering agent - Google Patents

Implant dosage form and use thereof for the delivery of a cholesterol lowering agent Download PDF

Info

Publication number
WO2002067895A3
WO2002067895A3 PCT/US2001/046714 US0146714W WO02067895A3 WO 2002067895 A3 WO2002067895 A3 WO 2002067895A3 US 0146714 W US0146714 W US 0146714W WO 02067895 A3 WO02067895 A3 WO 02067895A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
lowering agent
cholesterol lowering
dosage form
implant dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/046714
Other languages
French (fr)
Other versions
WO2002067895A2 (en
Inventor
Harry A J Struijker-Boudier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Priority to US10/432,644 priority Critical patent/US20040142902A1/en
Priority to EP01273052A priority patent/EP1335704A2/en
Priority to CA2429898A priority patent/CA2429898C/en
Publication of WO2002067895A2 publication Critical patent/WO2002067895A2/en
Publication of WO2002067895A3 publication Critical patent/WO2002067895A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Implanted, sustained release dosage forms, devices and methods for the delivery of a cholesterol lowering agent.
PCT/US2001/046714 2000-11-16 2001-11-08 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent Ceased WO2002067895A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/432,644 US20040142902A1 (en) 2001-11-08 2001-11-08 Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
EP01273052A EP1335704A2 (en) 2000-11-16 2001-11-08 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
CA2429898A CA2429898C (en) 2000-11-16 2001-11-08 Devices and methods for cholesterol management

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24964400P 2000-11-16 2000-11-16
US60/249,644 2000-11-16

Publications (2)

Publication Number Publication Date
WO2002067895A2 WO2002067895A2 (en) 2002-09-06
WO2002067895A3 true WO2002067895A3 (en) 2003-04-17

Family

ID=22944385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046714 Ceased WO2002067895A2 (en) 2000-11-16 2001-11-08 Implant dosage form and use thereof for the delivery of a cholesterol lowering agent

Country Status (3)

Country Link
EP (1) EP1335704A2 (en)
CA (1) CA2429898C (en)
WO (1) WO2002067895A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
US11110093B2 (en) 2005-09-30 2021-09-07 Indivior Uk Limited Sustained release small molecule drug formulation

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1578398A2 (en) * 2002-12-19 2005-09-28 ALZA Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
CA2520610A1 (en) 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
BRPI0408925A (en) 2003-03-31 2006-04-04 Alza Corp non-aqueous single phase vehicles and formulations using such vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20220023503A9 (en) 2007-05-10 2022-01-27 Aziyo Med, Llc Extracellular Matrix Tissue Prostheses
WO2008143992A2 (en) * 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
MX378797B (en) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc RAPID ESTABLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STEADY STATE DRUG SUPPLY.
WO2012087606A1 (en) * 2010-12-20 2012-06-28 Saint Joseph's Translational Research Institute, Inc. A drug eluting patch for the treatment of localized tissue disease or defect
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
EP2986278A1 (en) 2013-03-11 2016-02-24 DURECT Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
KR102574993B1 (en) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
WO2022040206A1 (en) 2020-08-17 2022-02-24 Aziyo Med, Llc Depots and encasement structures for implantable devices
CN116940358A (en) 2021-01-12 2023-10-24 度勒科特公司 Sustained release drug delivery system and related methods
WO2025147589A1 (en) * 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503520A1 (en) * 1991-03-12 1992-09-16 Glaxo Group Limited Cyclic ketal derivatives
US5837228A (en) * 1990-08-22 1998-11-17 Merck & Co., Inc. Bioerodible implants
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837228A (en) * 1990-08-22 1998-11-17 Merck & Co., Inc. Bioerodible implants
EP0503520A1 (en) * 1991-03-12 1992-09-16 Glaxo Group Limited Cyclic ketal derivatives
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE SCISEARCH [online] BUCHWALD H (REPRINT): "CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY", XP002221937, retrieved from STN Database accession no. 292994 *
DATABASE SCISEARCH [online] JOLES J (REPRINT) ET AL: "SUBCUTANEOUS ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS IN HYPERLIPEMIC AND NORMAL RATS", XP002221936, retrieved from STN Database accession no. 610133 *
LABORATORY ANIMALS, (OCT 1992) VOL. 26, NO. 4, PP. 269-280. ISSN: 0023-6772., UNIV UTRECHT, FAC MED, DEPT NEPHROL, UTRECHT, NETHERLANDS;UNIV UTRECHT, FAC MED, DEPT INTERNAL MED, UTRECHT, NETHERLANDS; UNIV UTRECHT, FAC MED, DEPT PHARMACEUT, UTRECHT, NETHERLANDS; ERASMUS UNIV, DE *
LANCET, (09 MAY 1992) VOL. 339, NO. 8802, PP. 1154-1156. ISSN: 0140-6736., UNIV MINNESOTA, DEPT SURG, BOX 290 UMHC, 420 DELAWARE ST SE, MINNEAPOLIS, MN, 55455 (Reprint) *
See also references of EP1335704A2 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US11110093B2 (en) 2005-09-30 2021-09-07 Indivior Uk Limited Sustained release small molecule drug formulation
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
US10376590B2 (en) 2007-05-25 2019-08-13 Indivior Uk Limited Sustained delivery formulations of risperidone compound
US11712475B2 (en) 2007-05-25 2023-08-01 Indivior Uk Limited Sustained delivery formulations of risperidone compound
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
CA2429898A1 (en) 2002-09-06
CA2429898C (en) 2011-02-22
EP1335704A2 (en) 2003-08-20
WO2002067895A2 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
AU2001281277A1 (en) Methods and devices for delivering a ventricular stent
AU2003276098A1 (en) Expandable medical implant and percutaneous delivery
IL152294A0 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2005027794A3 (en) Medical devices
WO2003028660A3 (en) Drug delivery devices and methods
AU2001273341A1 (en) An implantable or insertable therapeutic agent delivery device
AU8127701A (en) Methods and devices for delivering a ventricular stent
AU2002240275A1 (en) Methods and devices for delivering occlusion elements
AU2001296217A1 (en) Magnetically navigated pacing leads, and methods for delivering medical devices
AU2003258209A1 (en) Active agent delivery systems, medical devices, and methods
AU2001289098A1 (en) Implantable prosthesis
EP1143935A3 (en) Controlled-release biocompatible ocular drug delivery implant devices and methods
AU2001238386A1 (en) Medication delivery devices
WO2004010975A3 (en) Controlled drug delivery
AU2001254786A1 (en) Medical implant
AU2001295850A1 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
AU2003226770A1 (en) Intravaginal reservoir drug delivery devices
MXPA01011720A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods.
AU2001295979A1 (en) Medicinal compositions, dose and method for treating malaria
AU2607999A (en) Sustained release implant, methods for preparation thereof and for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2429898

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001273052

Country of ref document: EP

Ref document number: 2002258361

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001273052

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10432644

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP